Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the United States Patent and Trademark…
Sensible Biotechnologies is looking to mark its territory in the increasingly hot space of mRNA therapeutics, raising $47 million in a Series A round to develop its manufacturing approach.
Epicrispr Biotechnologies continued to show encouraging findings from testing of its epigenetic editing treatment for the genetic muscle disease facioscapulohumeral muscular dystrophy.
Nearly all respondents had personally cared for a pregnant woman (98 per cent) or baby (99 per cent) whose health they believed had been adversely affected by extreme heat, the study said
